

RESEARCH ARTICLE

Open Access

Chebulagic acid from *Terminalia chebula* causes G1 arrest, inhibits NFκB and induces apoptosis in retinoblastoma cells

Naresh Kumar[†], Gangappa D[†], Geetika Gupta and Roy Karnati^{*}

Abstract

Background: Plants are the valuable source of natural products with important medicinal properties. Most of the approved anti cancer drugs have a natural product origin or are natural products. Retinoblastoma is the most common ocular cancer of children. Although chemotherapy is the preferred mode of therapy, a successful treatment for retinoblastoma requires enucleation. Chebulagic acid (CA) from *Terminalia chebula* was shown to have anti-proliferative properties in the studies on cancerous cell lines. Due to anti cancer properties of CA and due to limitation in treatment options for retinoblastoma, the present study is undertaken to understand the role of CA on the proliferation of retinoblastoma cells.

Methods: Anti proliferative potential of CA was determined by MTT assay. The expression levels of various cell death mediators in retinoblastoma cells with CA treatment were assessed by Western blotting. Flowcytometer analysis was used to estimate the mitochondrial membrane potential (MMP) and to determine the percentage of cells undergoing apoptosis.

Results: The present study showed CA inhibited the proliferation of retinoblastoma cells in a dose dependent manner. CA modulated MMP, induced release of Cytochrome c, activated caspase 3 and shifted the ratio of BAX and Bcl2 towards cell death. G1 arrest, noticed in CA treated cells, is mediated by the increase in the expression of CDK inhibitor p27. CA treatment also decreased the levels of NFκB in the nucleus. This decrease is mediated by suppression in degradation of IκBα.

Conclusion: CA has shown significant anti proliferative potential on retinoblastoma cells. Our findings clearly demonstrate that CA induces G1 arrest, inhibits NFκB and induces apoptosis of retinoblastoma cells.

Keywords: Chebulagic acid, Retinoblastoma, Apoptosis

Background

Natural products from plants are considered as a valuable source of active drug substances and a majority of modern drugs. Drugs derived from plants or microbes which are in preclinical development or in clinical phase are discussed in detail elsewhere [1]. In addition to the stand alone natural products, there is also a growing interest in the combination of natural products, being effective or efficacious in a particular pathological condition and such combinations were also approved for human use by

regulatory authorities [2]. Plant derived natural products were also explored from treatment of cancers. Paclitaxel, camptothecin, etoposide, vinblastine and vincristine are all plant derived natural products approved for clinical use in many cancers. Epidemiological studies also show the beneficial effects of some fruit and vegetable diet against cancers [3,4]. Bioflavonoids, isoflavonoids, β carotenes, phenols, polyphenols, catechins, alkaloids, lectins were shown to have anti proliferative potential in several cancers [5-9].

Natural products alone or in combination with standard drugs were shown to be effective against retinoblastoma [10-12]. Retinoblastoma is the most common ocular tumor of children. In the majority of cases the survival

* Correspondence: roykarnati@gmail.com

[†]Equal contributors

School of Life Sciences, University of Hyderabad, Gachibowli, Hyderabad 500046, India

rate in retinoblastoma is almost 90% but successful treatment of retinoblastoma is achieved by enucleation [13]. At present treatment options include radiotherapy, chemotherapy, thermotherapy and brachytherapy [13,14]. Many complications arise due to the conventional therapies such as impaired vision due to cataracts and retinopathy [13], gastrointestinal disorders, neurotoxicity [15-19]. Carboplatin, etoposide and vincristine are synergistically used in chemotherapy of retinoblastoma [13]. Secondary cancers are induced due to the conventional therapies in children of lower age [14,20-22].

Inhibition of the molecular pathways having role in cell proliferation is a widely used strategy in anti cancer drug development. NFκB is an anti apoptotic transcription factor which plays an important role in the cell survival signaling. Interaction with IκB makes NFκB to reside in the cytoplasm as a dimer. Cell proliferation inducers mediate rapid degradation of IκB, promotes translocation of NFκB to the nucleus and induces the expression of several anti apoptotic protein including BCL2 family members [23,24]. p27 regulates cell cycle transition and increase in the expression of p27 arrests the cells in G1 phase and restricts entry into S phase. p27 is phosphorylated by CDK 2–cyclin E and this phosphorylation of p27 results in its degradation through ubiquitin mediated proteosomal degradation [25]. NFκB activity is constitutively required for the survival and proliferation of retinoblastoma cells [26].

Natural products are being explored for effective therapies and to reduce complications due to conventional chemotherapy in retinoblastoma. Few studies were successful in showing anti proliferative potential. Resveratrol inhibits proliferation of retinoblastoma cells by activating mitochondrial mediated apoptosis [27]. *Abelmoschus moschatus* extracts showed potent anti oxidant and anti proliferative activity in retinoblastoma [10]. Plant derived natural products like peruvoside, ouabain, neriifolin, digoxin, and digoxigenin induced greater than 75% inhibition in at least one retinoblastoma cell line [11]. Paclitaxel (PTX), a diterpene taxane, induced apoptosis in retinoblastoma cells along with beta lactophone [12].

In our previous studies we have shown CA from *Terminalia chebula* as a potent suppressor of lipopolysaccharide induced inflammation in mouse macrophages [28]. CA further showed broad spectrum anticancer effects on HCT-15 (colon), COLO-205 (colon) cell lines [29]. *Terminalia chebula*, a member of the *Combretaceae* family, native of India, is being used in alternative medicine. The dried fruits are being used for treatment for conditions of asthma, cough, bloody stools, heart and bladder disease [30]. The fruits are rich in high molecular weight tannins [31,32]. Benzopyran tannins are one of the major components in the fruits of *Terminalia chebula*. CA, a benzopyran tannin, was reported as a COX-2/5-LOX dual inhibitor [29]. CA has been shown to inhibit ROS generation [33] and anti-

hyperglycemic activity [34]. CA was also reported to alleviate arthritis in mice models [35] and inhibited LPS-induced Nitric oxide [36]. CA and punicalagin were shown to inhibit HSV-1 entry in A549 human lung cells by preventing binding, penetration, and cell-to-cell spread [37]. In addition to these reported studies, CA is the main constituent of Triphala, a well known ayurvedic medicine used to treat allergies and common health disorders in India.

Due to several important medicinal properties of CA and limitation of the current conventional therapies in retinoblastoma, the present study is undertaken to understand the effect of CA on the proliferation of retinoblastoma cells and elucidate the molecular mechanisms involved.

Methods

Chemicals

DMEM, FBS, Rhodamine 123, Propidium iodide were purchased from Gibco BRL. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide], protease inhibitor cocktail and TMB/H₂O₂, DAPI, Ac-DEVD-pNA, z-VAD-FMK were from Sigma-Aldrich. Nitrocellulose and PVDF membranes were from Millipore. Monoclonal antibodies of Cytochrome c, BAX, Bcl2, p27, NFκB-p65, IκBα and β-actin were from Cell Signaling technologies and Millipore. All the other chemicals and reagents were purchased from local companies and are of molecular biology grade. Chebulagic acid was isolated from fruits of *Terminalia chebula* as described previously [29]. Fruit material of *Terminalia chebula* (*Combretaceae*) authenticated by Prof. K. Seshagirao, and the dried drupes were deposited at University of Hyderabad Herbarium (UH) [University of Hyderabad, Hyderabad 500046, India] repository with Specimen No. 1006-KRRMR.

Cell culture

Retinoblastoma cells Y79 were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) heat-inactivated FBS, 100 IU/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine. Human corneal epithelial cells were grown in MEM alpha medium supplemented with EGF (0.1 mg/l) and insulin (5 mg/l). Both cultures were maintained in a humidified atmosphere with 5% CO₂ at 37°C. The cultured cells were passed twice each week, seeding at a density of approx. 2 × 10³ cells/ml. Cell viability was determined by the Trypan Blue dye exclusion method before seeding for each experiment.

Cell proliferation assay

Cell proliferation of Y79 cells with CA treatment was determined by the MTT assay. Y79 cells were seeded in 96-well plate in the presence or absence of CA (0.001, 0.01, 0.1, 0.5, 1, 5, 10, 25, 50 and 100 μM) for 24 h at a density of 5 × 10³ cells/well in a volume of 100 μl medium. After incubation, 20 μl of MTT at a concentration of 5 mg/ml was added.

After 4 h incubation at 37°C, 100 µl of lysis buffer was added to each well. Plates were agitated for 1 min and absorbance was read at 570 nm on a multi-well plate reader. The percentage of the inhibition of proliferation was calculated as a fraction of control (without CA treatment). To assess the effect of CA on non cancerous cells, Human corneal epithelial cells were used under similar treatment conditions.

Cell morphology analysis

Y79 cells (1×10^5) were incubated with CA (50 µM) for 24 h. Cells were observed and photographed for morphological changes under a phase contrast inverted microscope.

Nuclear morphology and DNA fragmentation analysis

Y 79 cells at a density of 1×10^5 were grown overnight in a cell culture dish. The cells were then incubated with CA (50 µM) for 24 h. After incubation, cells were washed with $1 \times$ PBS and mounted on to the slide with the mounting medium containing DAPI. The slides were then observed for changes in nuclear morphology in an Olympus inverted fluorescence microscope. For DNA fragmentation assay, Y 79 cells (5×10^6 cells) were incubated at 37°C with CA (50 µM) for 24 h. After treatment, cells were washed in cold PBS and lysed in a buffer containing 50 mM Tris (pH 8.0), 1 mM EDTA and 0.2% Triton X-100 for 20 min at 4°C. After centrifugation at 14 000 g for 15 min, the supernatant was treated with proteinase K (0.5 mg/ml) and 1% SDS for 1 h at 50°C. DNA was extracted twice with phenol and precipitated with 140 mM NaCl and 2 volumes of ethanol at -20°C overnight. DNA precipitates were washed twice in 70% (v/v) ethanol, dissolved in TE buffer, and treated for 1 h at 37°C with RNase A. Finally, DNA preparations were electrophoresed in 1% agarose gel, stained with ethidium bromide and observed under UV light.

Cell cycle analysis by flow cytometer

Y 79 cells were seeded at a density of 4×10^5 in 6-well culture plates, grown overnight in medium containing 10% FBS with or without CA (50 µM) for 24 h. After treatment cells were washed with $1 \times$ PBS. For the cell cycle analysis, cells were fixed in 70% ice cold ethanol, washed with $1 \times$ PBS, incubated with RNase A (0.1 mg/ml) and stained with propidium iodide (PI) (50 mg/ml). Flow cytometric analyses were performed by using a BD Calibur machine (San Jose, CA, U.S.A.) as previously described [38]. The fluorescence intensity of PI was detected with FL2-H detector. X axis on the histogram represents PI fluorescence intensity and Y axis represents number of cells at particular fluorescence intensity.

Measurement of mitochondrial membrane potential (MMP)

Y79 cells, at a density of 4×10^5 were seeded in 6-well culture plates and cultured with or without CA (50 µM) for

24 h. After the treatment, cells were incubated with Rhodamine 123 (10 µg/ml) for 30 min. After the incubation, cells were washed with $1 \times$ PBS. MMP was assessed on a flow cytometer. Data were collected using the data acquisition program CELL Questpro and fluorescence was measured using an FL-1H detector as previously described [38]. Ten thousand cells were analysed per sample. The fluorescence intensity of Rhodamine was detected with FL1-H detector. X axis on the dot plot represents Rhodamine fluorescence intensity and Y axis represents SSC-H (side scatter) indicating the granular content of the cells.

Assessment of caspase 3 activity

Caspase-3 activity in the lysates of Y79 cells treated with CA (50 µM) and untreated cells. 100 µg of total protein was incubated with Caspase 3 specific peptide (Ac-DEVD-pNA) at a final concentration of 200 µM at 37°C for 2 h in dark. The absorbance was read at 400 nm. Cells were pre-treated with a pan-caspase inhibitor (z-VAD-FMK) for 3 h at a concentration 20 µM before the cells were treated with CA (50 µM) and cell proliferation was estimated by MTT assay.

Western blotting

Y79 cells were seeded at a density of 5×10^6 in 100 mm culture dishes. They were incubated with CA (50 µM) for 0, 3, 6, 12, 24 and 48 h. After incubation with CA, cells were washed with $1 \times$ PBS and suspended in cell lysis buffer with 1 mM PMSE, 10 µg/ml leupeptin, 20 µg/ml aprotinin and phosphatase inhibitor cocktail. After 30 min of intermittent vortexing at 4°C, the cell lysate was centrifuged (10 000 g) for 30 min, and the supernatant were used as the whole cell extract. Nuclear and cytoplasmic extracts were also prepared as described previously [39]. The protein content was estimated by the Bradford method [40]. 100 µg of either total or nuclear or cytosolic protein from each treatment were resolved on 7–12% SDS PAGE gels along with protein molecular weight markers and then transferred on to nitrocellulose or PVDF membranes. Membranes were stained with 0.5% ponceau stain to check the transfer. The membranes were blocked with 5% (w/v) BSA and then incubated with the primary antibodies [BAX (1:250 dilution), Bcl-2,(1:500 dilution), Cytochrome c (1:250 dilution), p27 (1:500 dilution), NFκB-p65 (1:500 dilution), IκBα (1:500 dilution), β-actin (1:1000 dilution)] in 10 ml of antibody-dilution buffer ($1 \times$ Tris-buffered saline and 0.05% Tween 20 with 1% BSA) with gentle shaking at 4°C for 8–12 h and then incubated with peroxidase or alkaline phosphatase conjugated secondary antibodies. The signals were detected by using peroxidase or alkaline phosphatase substrates. The band intensity was quantified by Image J software.

Statistical analysis

Results are reported as the Mean \pm S. E. M. for three independent experiments. Statistical analysis was carried out by Student's t test. A p-value of less than 0.01 for each concentration versus control was considered to indicate significance.

Results

Y79 cell proliferation was inhibited by CA

Y79 cells were treated with CA (0.001, 0.01, 0.1, 0.5, 1, 5, 10, 25, 50 and 100 μ M) for 24 h and cell proliferation was determined by the MTT assay. CA treatment decreased the proliferation of Y79 cells in a dose dependent manner. At a concentration of 50 μ M of CA, a 50% decrease in Y79 cell proliferation was observed (Figure 1) in 24 h. Normal human corneal epithelial (HCE) cells were treated with CA at same concentration as that of Y79 cell treatment. CA at 50 μ M concentration could inhibit only 20% of HCE cell proliferation compared to 50% in Y79 cells. Further experiments were carried out with 50 μ M CA as 50% inhibition of Y79 cell proliferation was observed at this concentration.

Y79 cell morphology altered with CA treatment

Treatment of cells with cell death inducing agents alters the morphology of cells. Disruption of membrane and formation of membrane blebs are commonly observed. Untreated Y79 cells grow in grape like clusters (Figure 2A), but with CA treatment, morphology and growth pattern of the cells changed considerably. Y79 cells with CA treatment showed distorted morphology, membrane blebs and less clusters (Figure 2B).





Figure 1 Effect of CA on the proliferation of retinoblastoma and normal human corneal epithelial cells. Y79 and HCE cells were treated with 0.001, 0.01, 0.1, 0.5, 1, 5, 10, 25, 50 and 100 μ M concentration of CA for 24 h. The percentage of viable cells with treatment was calculated in comparison with untreated control cells. The number of cells in the control was taken as 100%. Data was represented as mean \pm S.E.M of three independent experiments. *P < 0.01 vs untreated control was considered to indicate significance.

(A)



(B)




Figure 2 Effect of CA on morphology of Y79 cells. (A) Control cells (B) CA (50 μ M; 24 h) treated cells.

CA induced nuclear and DNA fragmentation in Y 79 cells

Nuclear fragmentation, which is observed during apoptosis, is observed using a nuclear stain DAPI. In CA (50 μ M) treated cells, fragmented nuclei were observed (Figure 3B) and the nuclei were intact in untreated control cells (Figure 3A). Cells treated with CA (50 μ M) showed fragmentation of DNA, similar to the cells undergoing apoptosis (Figure 3C).

Mitochondrial membrane depolarization was observed with CA treatment

Mitochondria play a key role in apoptosis. A change in the membrane potential of mitochondria is a critical step in the induction of apoptosis. MMP was assessed using Rhodamine 123 by flow cytometric analysis. In Figure 4, X represents FL1-H, detector for Rhodamine in the flow cytometer. Y represents SSC-H, detector for granularity of cells. The cells on the higher scale of FL1-H represent cells with higher membrane potential. In control untreated cells majority of cells are on higher FL1H scale (Figure 4A). Treatment with CA 50 μ M, induced a shift in the significant cell population towards the lower scale of




Figure 3 Effect of CA on nucleus morphology and DNA fragmentation of Y79 cells. (A) DAPI stained nucleus of control cells (B) DAPI stained nucleus of CA (50 μ M; 24 h) treated cells (C) Lane 1, 100 bp DNA ladder; lane 2, DNA of control cells; lane 3, DNA of CA (50 μ M; 24 h) treated cells.

the FL1-H indicating depolarization of mitochondria (Figure 4B) and the treatment also resulted in decrease in cell granularity i.e. SSC-H, due to cell death.

Ratio of Bcl2 and BAX shifted towards apoptosis with CA treatment

Ratio of Bcl2 and BAX proteins decides the fate of the cells towards cell survival or cell death. Due to the decrease in the expression of anti-apoptotic protein Bcl2 and increase of expression of pro-apoptotic protein BAX, the cells die of apoptosis. Y79 cells treated with CA (50 μ M) showed a time dependent increase in expression of BAX (Figure 5A) and decrease in expression of Bcl2 until 24 h and total absence at 48 and 72 h (Figure 5B).

CA induced the release of Cytochrome *c*

Release of Cytochrome *c* into the cytosol as a result of mitochondrial depolarization initiates the intrinsic pathway of apoptosis. Western blot analysis with the cytoplasmic extracts devoid of mitochondria with anti-Cytochrome *c* antibodies was performed. A time dependent increase in


Cytochrome *c* release in Y79 cells treated with CA (50 μ M) was observed (Figure 5C). Untreated cells showed no release of Cytochrome *c*.

CA induced apoptosis is Caspase 3 dependent

Caspase-3 activity increased in the lysates of Y79 cells treated with CA (50 μ M) compared to that in untreated cells (Figure 6A). To show that CA induced cell death is caspase 3 dependent, MTT assay was done with CA, in the presence and absence of a pan-caspase inhibitor (z-VAD-FMK). Caspase inhibitor could inhibit the CA induced cell death in Y 79 cells (Figure 6B).

CA treatment increased the number of Y79 cells in hypodiploid and G1 phases


Number of hypodiploid cells increases with apoptosis. Induction of apoptosis with CA treatment was quantified by flowcytometric analysis. X represents FL2-H, detector for Propidium Iodide in the flow cytometer. Y represents counts, representing number of cells at particular FL2-H. Propidium Iodide is a DNA binding dye and proportion of



fluorescence emission is based on quantity of DNA in the cell. In a dividing cells, the quantity of DNA in different phases of cell cycle varies as $G1 < S < G2/M$. The marker (M1) represents the cells before G1 peak, indicating the cells which are having less DNA (hypodiploid) than G1 phase cells. These hypodiploid cells are the cells undergoing cell death. In the Figure 6, we can clearly observe, the increase in number of cells before G1 peak with CA (50 μM) treatment compared to untreated cells. Untreated control cells showed prominent G1 (59%), S (12%) and G2/M (27%) phases with minimal 1% in sub G1 hypodiploid stage (Figure 7A). Treatment with CA increased the% of cells in sub G1 phase and G1 phase to 12% and 76% respectively (Figure 7B). These results indicate that CA treatment arrested the cells in G1 stage of cell cycle and also induced apoptosis.

CA induces G1 arrest and inhibits NFκB



p27 and NFκB are important regulators of cell cycle progression and proliferation. As increase in% of cells in G1 phase was observed, the expression levels of p27 were estimated. With CA (50 μM) treatment, a time dependent increase in expression of p27 was observed (Figure 8C), indicating CA mediated G1 arrest is through p27. Levels of NFκB are altered with proliferative status of cells. NFκB-p65 levels decreased in the nuclear extracts of Y79



cells with CA treatment (Figure 8A), where as IκBα levels increased (Figure 8B). These results indicate CA suppressed the degradation of IκBα, there by inhibiting the translocation of NFκB to nucleus.

Discussion

Plants are the source of many clinically used potent anti-cancer molecules [1]. The enormous diversity of the plants was not explored and screened extensively for potential therapeutic molecules [41,42]. Exploration of plants for natural products even makes it more relevant these days, with the advances in the methods and technologies to prepare analogs from the isolated natural



products [43]. Our previous reports have shown the anti-cancer properties of natural products isolated from various sources [44-46]. Our group has shown CA isolated from *Terminalia chebula* inhibits LPS induced inflammation [28], inhibits proliferation of colon cancer cells [29]. In addition to these properties several groups have shown beneficial properties of CA [33-37]. Current therapies to retinoblastoma are limited necessitating the patient to undergo enucleation. Due to several medicinal properties of CA, the present study is planned to understand the effect of CA on retinoblastoma cell line, Y79, and to understand the molecular mechanisms involved.

Y79 cells when treated with CA showed a dose dependent inhibition of cell proliferation. We observed 50% inhibition of Y79 cell proliferation at 50 μ M concentration of CA. At the same concentration CA could only inhibit 20% proliferation of normal HCE cells. This indicates CA is more specific towards cancer cells. These differential effects of CA on cell proliferation between cancer and normal cells might be due to differences in constituent expression of the cellular protein signatures like constitutive NF κ B expression [26].

Retinoblastoma cells grow in clusters, but with the CA treatment, the morphology and growth pattern of the cells changed considerably. Y79 cells with CA treatment showed distorted morphology, membrane blebs and less cell clusters. Nuclear and DNA fragmentation, a hallmark property of cells undergoing apoptosis, was observed in Y79 cells with CA treatment.

MMP is critical for proper cellular functions. Depolarized mitochondria lead to leakage of the membrane leading to release of Cytochrome *c* and formation of apoptosome complex [47]. Rhodamine 123 was used to assess the MMP in CA treated Y79 cells by flowcytometric analysis. Treatment with CA decreased the MMP of the retinoblastoma




Figure 8 Effect of CA on the expression of NFκB-p65, IκBα and p27 proteins. Y79 cells treated with CA (50 μM) for different time periods (0, 3, 6, 12, 24 and 48 h). Equal amounts of total protein (IκBα, p27 and β-actin) and nuclear protein (NFκB-p65) (100 μg) was analysed by SDS-PAGE 7–12%, and after electrophoresis, proteins on the gel were transferred on to nitrocellulose membrane and probed with NFκB-p65, IκBα, p27 and β-actin specific antibodies. Lane 1, 0 h; lane 2, 3 h; lane 3, 6 h; lane 4, 12 h; lane 5, 24 h; lane 6, 48 h. Bar graphs represents mean relative expression of protein normalised against β-actin. (A) NFκB-p65, (B) IκBα, (C) p27, (D) β-actin.

cells, indicated by the movement of cells towards lower scale on x axis of the dot plot. This disruption of MMP might alter the membrane dynamics of mitochondria leading to the molecular events triggering cell death. Similar disruption in membrane potential was observed with methanolic extracts of *Gracilaria tenuistipitata* in oral cancer cells [38,48].

Bcl2 family members regulate the mitochondrial pathway of apoptosis. They are either pro apoptotic (Bak or Bax) or anti apoptotic (Bcl2 or Bcl XL). These proteins play role in permeabilization of the mitochondrial outer membrane on receiving apoptotic signals. Permeabilization leads to release of Cytochrome *c*, formation of apoptosome complex, activation of caspases, thus triggering morphological changes like membrane blebbing and nuclear

fragmentation. Expression ratio of pro apoptotic BAX and anti apoptotic Bcl2 is the critical factor in driving cells towards life or death. Cells undergoing apoptosis show an increase in the expression of BAX and a decrease in the expression of Bcl2. 7α-hydroxy-β-sitosterol, a natural phytosterol oxide was shown to induce apoptosis by altering Bcl2/BAX ratio [49]. In our study, Y79 cells treated with CA shifted the ratio of Bcl2 and BAX towards cell death by increasing expression of BAX and decreasing the expression of Bcl2, release of cytochrome *c* and activation of caspase 3.

NFκB is a proliferating promoting protein and is activated in majority of tumors. NFκB translocates to the nucleus and activates transcription of several genes which are involved in cell proliferation. Bcl2 expression is

defective in B cells that lack constituent proteins of NFκB indicating anti apoptotic Bcl2 might be regulated by NFκB [24]. The activation of NFκB is regulated by IκBα. We estimated the expression levels of NFκB and IκBα using western blotting. Treatment of retinoblastoma cells with CA inhibited the translocation of NFκB to the nucleus. CA suppressed the degradation of IκBα. This increase in levels of IκBα might have effected the translocation of NFκB to nucleus, effecting expression of several genes involved in Y79 cell proliferation. Similar NFκB mediated inhibition of cell proliferation was shown by natural products and plant extracts [50,51].

Most of the anti cancer agents target the cell cycle of the cancer cells and this property to alter the cell cycle is considered one of the important property in the anti cancer drug development [52]. Progression of cell cycle is regulated by CDK inhibitor, p27. Increase in the expression of p27 inhibits the cell cycle entry into S phase [25]. Cell cycle analysis of the Y79 cells treated with CA showed an increase apoptotic or hypodiploid cells. We could also observe an increase in number of cells in G1 phase with CA treatment. Western blot analysis of p27 also showed a time dependent increase in expression, which indicates that CA induces G1 arrest by the induction of p27 expression. The present study thus demonstrates that CA induces apoptosis in retinoblastoma cell line Y79 by altering expression of Bcl2 family members, activating caspase 3, disrupting MMP and interfering with the NFκB cell proliferation pathway (Figure 9).

Conclusions

Our findings clearly demonstrate that CA induces G1 arrest, inhibits NFκB and induces apoptosis of retinoblastoma Y79 cells. CA induced the release of Cytochrome c by

modulating the MMP and altering BAX and Bcl2 ratio towards apoptosis. CA induced apoptosis of Y79 cells is caspase 3 dependent. G1 arrest in the Y79 cells with CA treatment is mediated by the increase in the expression of CDK inhibitor p27. CA inhibited the nuclear translocation of NFκB by suppressing the degradation of IκBα. This study highlights the potential of CA in inhibiting the proliferation of retinoblastoma cells. Further studies are required to assess the in vivo anti proliferative potential of CA. CA and any other analogs derived from it may be explored and validated further for its usefulness as anti cancer agents for retinoblastoma and other cancers.

Abbreviations

CA: Chebulagic acid; CDK: Cyclin dependent kinase; COX: Cyclooxygenase; LOX: Lipoxygenase; FBS: Fetal bovine serum; DMEM: Dulbecco's modified eagle's medium; PBS: Phosphate buffered saline; MMP: Mitochondrial membrane potential.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

NK and GD carried out all the experiments, acquisition and analysis of data. GG was involved in cell culturing, MTT assay, Western blotting. RK conceived, designed, analysed and drafted the manuscript. All authors have read and approved the final manuscript.

Acknowledgements


This research is supported by grants from DST-SERB (No.SR/FT/LS-157/2010) to R. K. The research is done using DST-FIST supported infrastructural facilities. We are thankful to Lena Franziska Feige, University of Munster for her help in language corrections.

Received: 29 June 2013 Accepted: 20 August 2014

Published: 29 August 2014

References

- Butler MS: Natural products to drugs: natural product-derived compounds in clinical trials. *Nat Prod Rep* 2008, **25**:475-516.
- Newman DJ, Cragg GM: Natural products as sources of new drugs over the last 25 years. *J Nat Prod* 2007, **70**:461-477.
- Pak RW, Lanteri VJ, Scheuch JR, Sawczuk IS: Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. *Integr Cancer Ther* 2002, **1**:338-344.
- Vainio H, Weiderpass E: Fruit and vegetables in cancer prevention. *Nutr Cancer* 2006, **54**:111-142.
- Nakahata N, Kutsuwa M, Kyo R, Kubo M, Hayashi K, Ohizumi Y: Analysis of inhibitory effects of scutellariae radix and baicalin on prostaglandin E2 production in rat C6 glioma cells. *Am J Chin Med* 1998, **26**:311-323.
- Paiva SA, Russell RM: Beta-carotene and other carotenoids as antioxidants. *J Am Coll Nutr* 1999, **18**:426-433.
- Kale A, Gawande S, Kotwal S, Netke S, Roomi MW, Ivanov V, Niedzwiecki A, Rath M: A combination of green tea extract, specific nutrient mixture and quercetin: An effective intervention treatment for the regression of N-methyl-N-nitrosourea (MNU)-induced mammary tumors in Wistar rats. *Oncol Lett* 2010, **1**:313-317.
- Abdulla M, Gruber P: Role of diet modification in cancer prevention. *Biofactors* 2000, **12**:45-51.
- Zuzak TJ, Rist L, Eggenschwiler J, Grotzer MA, Viviani A: Pediatric medulloblastoma cells are susceptible to Viscum album (Mistletoe) preparations. *Anticancer Res* 2006, **26**:3485-3492.
- Gul MZ, Bhakshu LM, Ahmad F, Kondapi AK, Qureshi IA, Ghazi IA: Evaluation of *Abelmoschus moschatus* extracts for antioxidant, free radical scavenging, antimicrobial and antiproliferative activities using in vitro assays. *BMC Complement Altern Med* 2011, **11**:64.



11. Antczak C, Kleoppling C, Radu C, Genski T, Müller-Kuhrt L, Siems K, de Stanchina E, Abramson DH, Djabballah H: Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of cardenolides. *Invest Ophthalmol Vis Sci* 2009, **50**:3065–3073.
12. D'Anneo A, Augello G, Santulli A, Giuliano M, di Fiore R, Messina C, Tesoriere G, Vento R: Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt. *J Cell Physiol* 2010, **222**:433–443.
13. De Potter P: Current treatment of retinoblastoma. *Curr Opin Ophthalmol* 2002, **13**:331–336.
14. Abramson DH: Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. *Invest Ophthalmol Vis Sci* 2005, **46**:2683–2691.
15. Brichard B, De Bruycker JJ, De Potter P, Neven B, Vermeylen C, Cornu G: Combined chemotherapy and local treatment in the management of intraocular retinoblastoma. *Med Pediatr Oncol* 2002, **38**:411–415.
16. Benz MS, Scott IU, Murray TG, Kramer D, Toledano S: Complications of systemic chemotherapy as treatment of retinoblastoma. *Arch Ophthalmol* 2000, **118**:577–578.
17. Beck MN, Balmer A, Dessing C, Pica A, Munier F: First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. *J Clin Oncol* 2000, **18**:2881–2887.
18. Friedman DL, Himelstein B, Shields CL, Shields JA, Needle M, Miller D, Bunin GR, Meadows AT: Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. *J Clin Oncol* 2000, **18**:12–17.
19. Rizzuti AE, Dunkel IJ, Abramson DH: The adverse events of chemotherapy for retinoblastoma: what are they? Do we know? *Arch Ophthalmol* 2008, **126**:862–865.
20. Klein G, Michaelis J, Spix C, Wibbing R, Eggers G, Ritter J, Kaatsch P: Second malignant neoplasms after treatment of childhood cancer. *Eur J Cancer* 2003, **39**:808–817.
21. Nishimura S, Sato T, Ueda H, Ueda K: Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. *J Clin Oncol* 2001, **19**:4182–4183.
22. Chantada G, Fandiño A, Casak S, Manzitti J, Raslawski E, Schwartzman E: Treatment of overt extraocular retinoblastoma. *Med Pediatr Oncol* 2003, **40**:158–161.
23. Karin M, Lin A: NF-kappaB at the crossroads of life and death. *Nat Immunol* 2002, **3**:221–227.
24. Grossmann M, O'Reilly LA, Gugasyan R, Strasser A, Adams JM, Gerondakis S: The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. *EMBO J* 2000, **19**:6351–6360.
25. Schwartz GK, Shah MA: Targeting the cell cycle: a new approach to cancer therapy. *J Clin Oncol* 2005, **23**:9408–9421.
26. Poulaki V, Mitsiades CS, Joussem AM, Lappas A, Kirchoff B, Mitsiades N: Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability. *Am J Pathol* 2002, **161**:2229–2240.
27. Sareen D, van Ginkel PR, Takach JC, Mohiuddin A, Darjatmoko SR, Albert DM, Polans AS: Mitochondria as the primary target of resveratrol-induced apoptosis in human retinoblastoma cells. *Invest Ophthalmol Vis Sci* 2006, **47**:3708–3716.
28. Reddy DB, Reddanna P: Chebulagic acid (CA) attenuates LPS-induced inflammation by suppressing NF-kappaB and MAPK activation in RAW 264.7 macrophages. *Biochem Biophys Res Commun* 2009, **381**:112–117.
29. Reddy DB, Reddy TC, Jyotsna G, Sharan S, Priya N, Lakshminpathi V, Reddanna P: Chebulagic acid, a COX-LOX dual inhibitor isolated from the fruits of *Terminalia chebula* Retz., induces apoptosis in COLO-205 cell line. *J Ethnopharmacol* 2009, **124**:506–512.
30. Cheng HY, Lin TC, Yu KH, Yang CM, Lin CC: Antioxidant and free radical scavenging activities of *Terminalia chebula*. *Biol Pharm Bull* 2003, **26**:1331–1335.
31. Iason G: The role of plant secondary metabolites in mammalian herbivory: ecological perspectives. *Proc Nutr Soc* 2005, **64**:123–131.
32. Khanbabaee K, van Ree T: Tannins: classification and definition. *Nat Prod Rep* 2001, **18**:641–649.
33. Lee SI, Hyun PM, Kim SH, Kim KS, Lee SK, Kim BS, Maeng PJ, Lim JS: Suppression of the onset and progression of collagen-induced arthritis by chebulagic acid screened from a natural product library. *Arthritis Rheum* 2005, **52**:345–353.
34. Huang YN, Zhao DD, Gao B, Zhong K, Zhu RX, Zhang Y, Xie WJ, Jia LR, Gao H: Anti-Hyperglycemic Effect of Chebulagic Acid from the Fruits of *Terminalia chebula* Retz. *Int J Mol Sci* 2012, **13**:6320–6333.
35. Kinoshita S, Inoue Y, Nakama S, Ichiba T, Aniya Y: Antioxidant and hepatoprotective actions of medicinal herb, *Terminalia catappa* L. from Okinawa Island and its tannin coriagin. *Phytomedicine* 2007, **14**:755–762.
36. Murakami A, Ishida H, Kobo K, Furukawa I, Ikeda Y, Yonaha M, Aniya Y, Ohigashi H: Suppressive effects of Okinawan food items on free radical generation from stimulated leukocytes and identification of some active constituents: implications for the prevention of inflammation-associated carcinogenesis. *Asian Pac J Cancer Prev* 2005, **6**:437–448.
37. Lin LT, Chen TY, Chung CY, Noyce RS, Grindley TB, McCormick C, Lin TC, Wang GH, Lin CC, Richardson CD: Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. *J Virol* 2011, **85**:4386–4398.
38. Roy KR, Arunasree KM, Reddy NP, Dheeraj B, Reddy GV, Reddanna P: Alteration of mitochondrial membrane potential by *Spirulina platensis* C-phycoyanin induces apoptosis in the doxorubicin resistant human hepatocellular carcinoma cell line HepG2. *Biotechnol Appl Biochem* 2007, **47**:159–167.
39. Roy KR, Arunasree KM, Dhoot A, Aparna R, Reddy GV, Vali S, Reddanna P: C-Phycocyanin inhibits 2-acetylaminofluorene-induced expression of MDR1 in mouse macrophage cells: ROS mediated pathway determined via combination of experimental and In silico analysis. *Arch Biochem Biophys* 2007, **459**:169–177.
40. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976, **72**:248–254.
41. Harvey A: Strategies for discovering drugs from previously unexplored natural products. *Drug Discov Today* 2000, **5**:294–300.
42. Baker DD, Chu M, Oza U, Rajgarhia V: The value of natural products to future pharmaceutical discovery. *Nat Prod Rep* 2007, **24**:1225–1244.
43. Sunazuka T, Hirose T, Omura S: Efficient total synthesis of novel bioactive microbial metabolites. *Acc Chem Res* 2008, **41**:302–314.
44. Nishanth RP, Ramakrishna BS, Jyotsna RG, Roy KR, Reddy GV, Reddy PK, Reddanna P: C-Phycocyanin inhibits MDR1 through reactive oxygen species and cyclooxygenase-2 mediated pathways in human hepatocellular carcinoma cell line. *Eur J Pharmacol* 2010, **649**:74–83.
45. Roy KR, Nishanth RP, Sreekanth D, Reddy GV, Reddanna P: C-Phycocyanin ameliorates 2-acetylaminofluorene induced oxidative stress and MDR1 expression in the liver of albino mice. *Hepatol Res* 2008, **38**:511–520.
46. Sreekanth D, Arunasree MK, Roy KR, Chandramohan Reddy T, Reddy GV, Reddanna P: Betanin a betacyanin pigment purified from fruits of *Opuntia ficus-indica* induces apoptosis in human chronic myeloid leukemia Cell line-K562. *Phytomedicine* 2007, **14**:739–746.
47. Chinnaiyan AM: The apoptosome: heart and soul of the cell death machine. *Neoplasia* 1999, **1**:5–15.
48. Yeh CC, Yang JI, Lee JC, Tseng CN, Chan YC, Hseu YC, Tang JY, Chuang LY, Huang HW, Chang FR, Chang HW: Anti-proliferative effect of methanolic extract of *Gracilaria tenuistipitata* on oral cancer cells involves apoptosis, DNA damage, and oxidative stress. *BMC Complement Altern Med* 2012, **12**:142.
49. Tasyriq M, Najmuldeen IA, In LL, Mohamad K, Awang K, Hasima N: α -Hydroxy- β -Sitosterol from *Chisocheton tomentosus* Induces Apoptosis via Dysregulation of Cellular Bax/Bcl-2 Ratio and Cell Cycle Arrest by Downregulating ERK1/2 Activation. *Evid Based Complement Alternat Med* 2012, **2012**:765316.
50. Deeb D, Jiang H, Gao X, Hafner MS, Wong H, Divine G, Chapman RA, Dulchavsky SA, Gautam SC: Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkkappaBalpha phosphorylation. *Mol Cancer Ther* 2004, **3**:803–812.
51. Lopes FC, Rocha A, Pirraco A, Regasini LO, Silva DH, Bolzani VS, Azevedo I, Carlos IZ, Soares R: Anti-angiogenic effects of pterogynidine alkaloid isolated from *Alchornea glandulosa*. *BMC Complement Altern Med* 2009, **9**:15.
52. Carnero A: Targeting the cell cycle for cancer therapy. *Br J Cancer* 2002, **87**:129–133.

doi:10.1186/1472-6882-14-319

Cite this article as: Kumar et al.: Chebulagic acid from *Terminalia chebula* causes G1 arrest, inhibits NFkB and induces apoptosis in retinoblastoma cells. *BMC Complementary and Alternative Medicine* 2014 **14**:319.